Find out how a proactive approach to site augmentation helps enroll over 30,000 vaccine study participants in just over three months.
As COVID-19 spread around the world, the accompanying lockdowns and travel restrictions brought many challenges for clinical trials. At the same time, there was an urgent effort to develop and test vaccines and therapeutics. These endeavors required enrolling tens of thousands of trial participants as quickly as possible, creating a huge burden on clinical trial sites that were already trying to figure out how to continue work during a global health emergency.
Thank you for your interest.Download Now
Enter the 6 digit code sent to your mobile number
Click on Resend the verification code again